Southern Archipelago (A33) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
5 Nov, 2026Executive summary
FY2024 was a challenging year amid global uncertainty, market volatility and restructuring; strategic priorities shifted to strengthening existing assets and pausing new hospitality and wellness acquisitions.
Revenue was S$4.82m and profit before tax was S$0.24m; after S$0.39m income tax expense, the year ended with a S$0.15m net loss.
Financial highlights
Revenue fell to S$4.817m from S$5.196m in FY2023; the stated main cause was translation loss from a stronger Singapore dollar against the Indonesian rupiah.
Profit before tax declined to S$235,529 from S$587,258; net result swung to a S$152,723 loss from S$44,433 profit, with basic and diluted loss per share of 0.0006 cents.
Other gains, net, were S$272,015 versus S$463,377; interest income was S$12,120 versus S$52,105, while total expenses were S$4.865m versus S$5.125m.
Operating cash flow was S$228,611 versus S$1.065m; investing cash outflow was S$5.082m, including S$5.029m property and equipment purchases, and closing cash was S$414,142.
Outlook and guidance
FY2025 is expected to remain challenging; focus is on reassessing the portfolio, investing in existing businesses and pursuing organic growth or strategic acquisitions when conditions improve.
Sterilisation capacity expansion is underway, with the business expected to remain a sizeable revenue contributor; no quantified financial guidance was stated.
Hospitality and wellness acquisition plans are paused while market conditions and opportunities are reassessed.
Latest events from Southern Archipelago
- Sterilisation recovery continues, but liquidity strains and a covenant breach cloud the outlook.A33
Q3 2026 - Revenue and net profit improved, but liquidity and diversification remain key challenges.A33
H2 2023 - A return to modest profit meets weaker revenue and widening working-capital pressure.A33
H1 2024 - Sterilisation growth plans amid a S$566k loss, negative working capital and covenant risk.A33
H1 2025 - Revenue fell 17.8%; upgraded capacity meets a strained balance sheet and recovery test.A33
H2 2025 - Revenue fell 47% amid Indonesian headwinds, with liquidity and covenant risks still acute.A33
Q1 2026 - Sterilisation rebounded in 2Q, but liquidity pressure and a loan covenant breach persist.A33
H1 2026